

# VACCINATION

[www.nurseinfo.in](http://www.nurseinfo.in)



# EPI Vaccination Schedule

## Vaccine

### **BCG - (Live vaccine)**

**BCG**

**Bacillus Calmette -Guérin**

**Against Disease**

**Tuberculosis**

**Ideal age**

**At Birth**

**Important : Instruction**

**(only one dose)**

**(within 1 week) to mother about Scar**

**Dose**

**0.05 ml**

**Form**

**Powdered**

**Site**

**Deltoid muscle (Rt. Arm)**

**Route of**

**Intra-Dermal**

**Administration**

**Rare - Scar after 3-6 months**

**Side Effect**

**80% against Pulmonary TB**

**Immunity Achieved**

**100% against Tuberculous Meningitis  
(TBM)**

# EPI Vaccination Schedule

## Vaccine

# **OPV - (Live vaccine)**

<b>OPV</b>	<b>Oral Polio Vaccine</b>
<b>Against Disease</b>	<b>Poliomyelitis</b>
<b>Ideal age (four doses)</b>	<b>At Birth OPV0(within 1 week), 6 (OPV1),10 (OPV2) &amp; 14 (OPV3) weeks</b>
<b>Dose</b>	<b>Two drops</b>
<b>Form</b>	<b>Liquid</b>
<b>Site</b>	<b>Mouth</b>
<b>Route of Administration</b>	<b>Orally</b>
<b>Side Effect</b>	<b>No</b>
<b>Immunity Achieved</b>	<b>70% In Developing countries 100% In Developed countries</b>

## EPI Vaccination Schedule

### Vaccine

# Measles (Live Vaccine)

**Against Disease**

**Measles**

**Ideal age (two  
doses)**

**At 9 months & 15 months (Booster)**

**Dose**

**0.5 ml**

**Form**

**Powdered**

**Site**

**Deltoid muscle (Lt. Arm)**

**Route of  
Administration**

**Sub-Cutaneous**

**Side Effect**

**Generally No**

**Immunity Achieved**

**95 - 98%**

# EPI Vaccination Schedule

## Vaccine

**PENTA**

## **PENTA**

**D + P + T + HBV + HIB**

**(Toxoid-D&T, Dead-P& others HBV & HIB)**

### **Against Disease**

**Diphtheria, Pertussis, Tetanus,  
Hepatitis B & Haemophilus Influenza  
virus B**

### **Ideal age (three doses)**

**6 (Penta1), 10 (Penta2) & 14 (Penta3)  
weeks**

### **Dose**

**0.5 ml**

### **Form**

**Powdered**

### **Site**

**Antero-Lateral site - Mid Left Thigh  
Intra-Muscular**

### **Route of Administration**

**Fever, tenderness Injection site &  
Rarely fits**

### **Side Effect**

**95 - 98 %**

### **Immunity Achieved**

# EPI Vaccination Schedule

Vaccine

## PCV

(other name)

### Pneumococcal Vaccine

PCV

Against Disease

Due to Pneumococcal bacteria  
(Pneumonia, Meningitis etc.)

Ideal age (three doses)

6 (PCV1), 10 (PCV2) & 14 (PCV3)  
weeks

Dose

0.5 ml

Form

Liquid

Site

Antero-Lateral site – Mid Right  
Thigh

Route of

Intra-Muscular

Administration

Side Effect

Generally No

Immunity Achieved

95 - 98%

# EPI Vaccination Schedule

Vaccine	<b>TT</b>
TT	<b>Tetanus Toxoid</b>
Against Disease	<b>Tetanus</b>
Ideal age (five doses)	<b>According to schedule</b>
Dose	<b>0.5 ml</b>
Form	<b>Liquid</b>
Site	<b>Deltoid muscle – Left Arm</b>
Route of Administration	<b>Intra-Muscular</b>
Side Effect	<b>Generally No</b>
Immunity Achieved	<b>100%</b>

# EPI Vaccination Schedule

## Vaccine

### **BCG - (Live vaccine)**

**BCG**

**Bacillus Calmette -Guérin**

**Against Disease**

**Tuberculosis**

**Ideal age**

**At Birth**

**Important : Instruction**

**(only one dose)**

**(within 1 week) to mother about Scar**

**Dose**

**0.05 ml**

**Form**

**Powdered**

**Site**

**Deltoid muscle (Rt. Arm)**

**Route of**

**Intra-Dermal**

**Administration**

**Rare - Scar after 3-6 months**

**Side Effect**

**80% against Pulmonary TB**

**Immunity Achieved**

**100% against Tuberculous Meningitis  
(TBM)**

# Vaccination Schedule for Females 15- 45 years (Child Bearing Age - CBA)

Tetanus Toxoid	TT <sub>1</sub>	TT <sub>2</sub>	TT <sub>3</sub>	TT <sub>4</sub>	TT <sub>5</sub>
Intra-Muscular	At 1 <sup>st</sup> Contact as early as possible OR during 7 <sup>th</sup> months of	At least 4 Weeks after TT <sub>1</sub>	At least 6- 12 Months after TT <sub>2</sub>	At least 1 year after TT <sub>3</sub>	At least 1 year after TT <sub>4</sub>
Immunity Achieved	No	3 years	5 years	10 years	20 years OR Live long

# EPI Vaccination Schedule

Age	Vaccines to be given	Dose	Form	Site	Route of Administration
At Birth	BCG OPV0	0.05 ml	Powdered	Deltoid (Rt. Arm)	Intra-Dermal Oral
At 6 Weeks	PENTA1 (DPT1 + HBV1 + HIB1) OPV1	0.5 ml	Liquid	Ant. Lat. Lt. Thigh	Intra-Muscular Oral
	PCV1	0.5 ml	Liquid	Rt. Thigh	Intra-Muscular
At 10 Weeks	PENTA2 (DPT2 + HBV2 + HIB2) OPV2	0.5 ml	Liquid	Ant. Lat. Lt. Thigh	Intra-Muscular Oral
	PCV2	0.5 ml	Liquid	Rt. Thigh	Intra-Muscular
At 14 Weeks	PENTA3 (DPT3 + HBV3 + HIB3) OPV3	0.5 ml	Liquid	Ant. Lat. Lt. Thigh	Intra-Muscular Oral
	PCV3	0.5 ml	Liquid	Rt. Thigh	Intra-Muscular
At 9 Months	Measles	0.5 ml	Powdered	Deltoid (Lt. Arm)	Sub-Cutaneous
At 15 Months (Booster)	Measles	0.5 ml	Powdered	Deltoid (Lt. Arm)	Sub-Cutaneous

	<b>IPV</b>	<b>Fractional IPV (fIPV)</b>
<b>Volume per dose</b>	0.5 mL	0.1 mL
<b>Schedule</b>	<b>1 dose:</b> 14 weeks	<b>2 doses:</b> 6 and 14 weeks
<b>Administration</b>	Intramuscular (IM) injection	Intradermal (ID) injection
<b>Site of administration</b>	Thigh	Upper arm
<b>Syringe</b>	0.5 mL AD syringe	0.1 mL AD syringe
<b>Are two fractional doses as effective as a single standard dose?</b>	Two fractional doses of IPV (ID) given at 6 and 14 weeks produces better immunogenicity than a single standard dose (IM) given at 14 weeks	

# EPI Vaccination Schedule

## Vaccine

# **OPV - (Live vaccine)**

**OPV**

**Oral Polio Vaccine**

**Against Disease**

**Poliomyelitis**

**Ideal age (four  
doses)**

**At Birth OPV0(within 1 week), 6  
(OPV1),10 (OPV2) & 14 (OPV3) weeks**

**Dose**

**Two drops**

**Form**

**Liquid**

**Site**

**Mouth**

**Route of**

**Orally**

**Administration**

**No**

**Side Effect**

**Immunity Achieved**

**70% In Developing countries**

**100% In Developed countries**

- Diphtheria
- Pneumonia
- Hepatitis B
- Measles
- Meningitis
- Mumps
- Pertussis
- Poliomyelitis
- Rubella
- Tetanus
- Tuberculosis
- Yellow Fever

# VACCINE PREVENTABLE DISEASES

A vaccine-preventable disease is an infectious disease for which an effective preventive vaccine exists.(1)

25 Diseases – WHO. (2)



### Live attenuated (LAV)

- Tuberculosis (BCG)
- Oral polio vaccine (OPV)
- Measles
- Rotavirus
- Yellow fever

### Inactivated (killed antigen)

- Whole-cell pertussis (wP)
- Inactivated polio virus (IPV)

### Subunit (purified antigen)

- Acellular pertussis (aP),
- *Haemophilus influenzae* type B (Hib),
- Pneumococcal (PCV-7, PCV-10, PCV-13)
- Hepatitis B (HepB)

### Toxoid (inactivated toxins)

- Tetanus toxoid (TT),
- Diphtheria toxoid

# CLOSE THE IMMUNIZATION GAP



IMMUNIZATION FOR ALL  
THROUGHOUT LIFE

## SIX GOALS OF THE GLOBAL VACCINE ACTION PLAN



### IMMUNIZATION AGAINST DIPHTHERIA, TETANUS AND PERTUSSIS

Target



Immunization coverage with 3 doses of diphtheria, tetanus and pertussis vaccines

Gap: **65 countries**

18.7 million children unvaccinated



### MEASLES MORTALITY REDUCTION

Target



At least 4 WHO Regions to eliminate measles in 2015



Gap: **15%**

15% of all children not being immunized with one dose. Only one Region has eliminated measles

### RUBELLA ELIMINATION

Target



Eliminate rubella from at least two WHO regions in 2015



Gap: **1/2**

Half of all children do not receive the rubella vaccine

### MATERNAL AND NEONATAL TETANUS ELIMINATION

Target



Eliminate maternal and neonatal tetanus in 59 priority countries

Gap: **21 countries**

21 countries have not yet eliminated maternal and neonatal tetanus



### POLIO ERADICATION

Target



A world free of polio




Gap: **2 countries**

Remain polio endemic

### USE OF NEW OR UNDERUTILIZED VACCINES

Target



At least 90 low- and middle-income countries introduce one or more new or underutilized vaccine



On **TRACK**

86 low- and middle-income countries added at least one new or underutilized vaccine

## EPI Vaccination Schedule

### Vaccine

# Measles (Live Vaccine)

**Against Disease**

**Measles**

**Ideal age (two  
doses)**

**At 9 months & 15 months (Booster)**

**Dose**

**0.5 ml**

**Form**

**Powdered**

**Site**

**Deltoid muscle (Lt. Arm)**

**Route of  
Administration**

**Sub-Cutaneous**

**Side Effect**

**Generally No**

**Immunity Achieved**

**95 - 98%**